RenovoRx to Participate in Upcoming October 2022 Investor Conferences

Logos - Roth Capital Partners and LDMicro

Los Altos, CA, October 4, 2022 – RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform, today announced management’s participation in two upcoming investor conferences this month. Conferences include ROTH Inaugural Healthcare Opportunities, October 6th,  and LD Micro Main Event XV, October 25th-27th.

Shaun Bagai, RenovoRx’s CEO, will provide a corporate update during his presentations. He will also discuss current available treatment options for pancreatic tumors, why they can fall short of providing an effective solution for treating this deadly disease, and how RenovoRx’s therapy platform re-envisions the treatment of pancreatic and other difficult-to-treat cancers. During the conferences, Shaun will participate in one-on-one meetings with the investment community. Attendees include public companies, and institutional and private investors. To schedule a meeting, please reach out to your conference representative or send an email to KCSA Strategic Communications at

ROTH Inaugural Healthcare Opportunities Conference
Format and Dates: In-person, October 6, 2022
Location: Club Quarters Hotel Grand Central, New York, New York
Presenter: Shaun Bagai, CEO
Presentation Date and Time: Thursday, October 6th at 12:40 p.m. ET

LD Micro Main Event XV
Format and Dates: In-person, October 25-27th, 2022
Location: Luxe Sunset Boulevard Hotel, Los Angeles, California
Presenter: Shaun Bagai, CEO
Presentation Date and Time: Wednesday, October 26th at 12:30 p.m. PT

About RenovoRx, Inc.

RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult-to-treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and our patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.

RenovoRx’s patent portfolio for its therapy platform and product candidates includes seven U.S. patents, one European patent and several additional patents pending in the US, EU, and Asia. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.

RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.

Learn more by visiting the RenovoRx website or following us on FacebookLinkedIn and Twitter.

Company Contact:

RenovoRx, Inc.
Shaun R. Bagai, CEO
James Ahlers, CFO

Investor Contact:

KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254

Previous Post
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer
Next Post
RenovoRx Reports Third Quarter 2022 Financial Results